SGLT2 Inhibitors are a readily available group of medicines that were initially developed for diabetes.  They have recently been shown to be capable of cutting the loss of kidney function in half.  Background Each year, an estimated 1.5 million Americans are diagnosed with diabetes. The effect of diabetes on the kidneys varies greatly from person […]